Sonoma Pharmaceuticals
Manufacturing · Colorado, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
5445 Conestoga Ct Ste 150, Boulder, Colo...Phone Number
(707) 283-0550Website
www.sonomapharma.comRevenue
$19.5 MillionStock Symbol
SNOAIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Sonoma Pharmaceuticals
Sonoma Pharmaceuticals began with HOCl based products for wound care patients. After significant success helping millions of patients, Sonoma has since expanded into dermatology, eye care and animal health. Today, Sonoma is the global leader in HOCl based health care solutions. Sonoma Pharmaceuticals is a global scientific healthcare company that has pioneered the use of Hypochlorous Acid (HOCl) in the specialty pharmaceutical sector. We develop safe and effective early-intervention solutions that provide fast relief and are free from side effects and other limitations. Our primary focus is developing innovative solutions for dermatological conditions, eye care and advanced tissue care. We have used our superior knowledge and application of HOCl to better the lives of millions around the world.Explore more
Sonoma Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Sonoma Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Sonoma Pharmaceuticals had a recent Job posting/layoffs
Product Launch: Get notified when Sonoma Pharmaceuticals launches new products
Earning: See what the market has to say on Sonoma Pharmaceuticals recently announced quarterly report
Check out if Sonoma Pharmaceuticals is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Sonoma Pharmaceuticals
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Sonoma Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Sonoma Pharmaceuticals has new funding data
Check if Sonoma Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Sonoma Pharmaceuticals
Find 3 more new buyers
Compare Similar Companies to Sonoma Pharmaceuticals
Compare insights from companies similar to Sonoma Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Sonoma Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Sonoma Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Sonoma Pharmaceuticals.
Sonoma Pharmaceuticals financials insights
Gather financial insights about Sonoma Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2007
Stock Offering
$24.2M
2020
Debt
$1M
Sonoma Pharmaceuticals Tech Stack
A closer look at the technologies used by Sonoma Pharmaceuticals
Most Recent Scoops
Earnings
reported an 18% increase in overall revenues and a 57% increase in U.S. revenues for the first quarter of the fiscal year ending June 30, with continued improvement on the bottom line.
Project
Sonoma Pharmaceuticals has announced that its hypochlorous acid products are effective against bacteria, fungi, and viruses while promoting healing. The products are used for wound care, burns, lacerations, dermatological conditions, and have claims for atopic dermatitis and scar treatment.
Project
Sonoma Pharmaceuticals is celebrating its 20th year of business in Europe and has been listed on Nasdaq for over 20 years. The company is a leader in hypochlorous acid technology, with applications in wound care, eye care, dermatology, podiatry, animal health, and non-toxic disinfectants.
Product Launch
continues to invest in R&D, consistently developing new products and obtaining regulatory approvals. The company has launched its first OTC product, a baby diaper rash wash, in Walmart and on Amazon, with plans to expand into other large retailers and supermarkets.
Project
Sonoma Pharmaceuticals News & Media
Sonoma Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Sonoma Pharmaceuticals ( NASDAQ:SNOA ) Third Quarter 2024 Results Key Financial Results Revenue: US$3.14m (up 6.6% from...NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor Network
EMERYVILLE, Calif. & BOULDER, Colo.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced an agreement for the sale and marketing of Avenova®-branded products by Sonoma in the European Union. The new products will combine Sonoma’s existing eye product Ocudox®, which has already received a Class IIB CE mark for sale in the European Union, with Avenova branding, and are expected to be marketed through Sonoma’s establisSonoma Pharmaceuticals and EMC Pharma Announce Department of Defense DAPA Registration for Microcyn(R) Rx Products
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including dermatology, eye, oral and nasal care, and wound care, today announced that Microcyn® Rx products have received a Distribution and Pricing Agreement (DAPA) for distribution by the Defense Logistics Agency (DLA).Sonoma Pharmaceuticals Second Quarter 2023 Earnings: US$0.33 loss per share (vs US$0.043 loss in 2Q 2022)
Sonoma Pharmaceuticals ( NASDAQ:SNOA ) Second Quarter 2023 Results Key Financial Results Revenue: US$3.33m (down 11...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Sonoma Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Sonoma Pharmaceuticals began with HOCl based products for wound care patients. After significant success helping millions of patients, Sonoma has since expanded into dermatology, eye care and animal health. Today, Sonoma is the global leader in HOCl based health care solutions. Sonoma Pharmaceuticals is a global scientific healthcare company that h... Read More
